Perspectives in the treatment of vascular dementia

Drugs of Today

Volumn 36, Issue 9, 2000, Pages 641-653

  Roman, G ^a  

^a UT Memory Disorders/Dementia Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AKATINOL MEMANTINE; ANTITHROMBOCYTIC AGENT; BUFLOMEDIL; CALCIUM CHANNEL BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CINNARIZINE; CITICOLINE; DENBUFYLLINE; DIHYDROERGOTOXINE MESILATE; DONEPEZIL; ERGOT DERIVATIVE; GINKGO BILOBA EXTRACT; ISOXSUPRINE; MEMANTINE; NAFTIDROFURYL; NAFTIDROFURYL OXALATE; NICARDIPINE; NICERGOLINE; NIMODIPINE; NOOTROPIC AGENT; OXIRACETAM; OXYGEN; PENTOXIFYLLINE; PIRACETAM; PROPENTOFYLLINE; RIVASTIGMINE; STUGERONT; SULODEXIDE; TRIFLUSAL; UNINDEXED DRUG; VASODILATOR AGENT; XANTHINE DERIVATIVE;

ALZHEIMER DISEASE; BINSWANGER ENCEPHALOPATHY; CLINICAL FEATURE; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DIABETES MELLITUS; DIAGNOSTIC APPROACH ROUTE; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERBARIC OXYGEN; HYPERTENSION; MEMORY; MULTIINFARCT DEMENTIA; NONHUMAN; REVIEW; RISK FACTOR; STROKE; TREATMENT OUTCOME;

EID: 0033788973     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2000.36.9.593781     Document Type: Review

References (110)

1. Pathology and pathophysiology of cerebrovascular dementia: Pure subgroups of obstructive and hypoperfusive etiology
2. How acute brain failure becomes chronic: A view of the mechanisms of dementia related to stroke
3. Vascular dementia
4. Concept of pre-stroke dementia
5. Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop
6. Clinical trials in dementia with propentofylline
7. Research criteria for subcortical vascular dementia in clinical trials
8. Dementia three months after stroke: Baseline frequency and effect of different definitions of dementia in the Helsinki Stroke Aging Memory Study (SAM) cohort
9. Cranial computed tomographic observations in multi-infarct dementia: A controlled study
10. A quantitative MRI study of vascular dementia
11. Risk factors for incident dementia after stroke: Role of hypoxic ischemic disorders
12. Vascular dementia
13. Prevalence of dementia after stroke depends on diagnostic criteria
14. Dementia as a predictor of adverse outcomes following stroke: An evaluation of diagnostic methods
15. The prevalence and malignancy of Alzheimer's disease, a major killer
16. 'Cerebroacfive' drugs: Clinical pharmacology and therapeutic role in cerebrovascular disorders
17. Concluding remarks
18. Vasodilators in senile dementias: A review of the literature
19. Overview of clinical trials of Hydergine in dementia
20. A new scale for clinical assessment in geriatric population: Sandoz Clinical Assessment Geriatric (SCAG)
21. Hydergine for dementia
22. Comparison of the calcium entry blockers nimodipine and fiunarizine on human cerebral and temporal arteries: Role in cerebrovascular disorders
23. Long-term effects of nimodipine on cerebral infarcts and outcome after aneurysmal subarachnoid hemorrhage and surgery
24. Cytosolic free calcium during focal cerebral ischemia and the effects of nimodipine on calcium and histologic damage
25. Formation of cerebrovascular anomalies in the ageing rats is delayed by chronic nimodipine application
26. Nimodipine for primary degenerative, mixed and vascular dementia
27. The Scandinavian Multi-Infarct Dementia Trial: A double blind, placebo controlled trial on nimodipine in multi-infarct dementia
28. Efficacy and safety of nimodipine in subcortical vascular dementia: A subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial
29. A preliminary open trial with nimodipine in patients with cognitive impairment and leukoaraiosis
30. Nimodipine in subcortical vascular dementia trial
31. A study of the tolerability and effectiveness of nicardipine retard in cognitive deterioration of vascular origin
32. An experimental, randomized, double-blind, placebo-controlled clinical trial to investigate the effect of nicardipine on cognitive function in patients with vascular dementia
33. The effects of nicardipine on dynamic cerebral autoregulation in patients anesthetized with propofol and fentanyl
34. Reduction of cerebral hyperemia with antihypertensive medication after electroconvulsive therapy
35. Pharmacological properties of piracetam
36. Piracetam for dementia or cognitive impairment
37. Piracetam and other structurally related nootropics
38. Oxiracetam in the treatment of multi-infarct dementia and primary degenerative dementia
39. Neuropsychological results of long-term therapy with oxiracetam in patients with dementia of Alzheimer type and multi-infarct dementia in comparison with a control group
40. Oxiracetam in dementia: A double-blind, placebo-controlled study
41. Clinical studies with oxiracetam in patients with dementia of the Alzheimer type and multi-infarct dementia of mild to moderate degree
42. Antioxidant properties of nicergoline: Inhibition of brain auto-oxidation and superoxide production of neutrophils in rats
43. A multicenter randomized double-blind study on the efficacy and safety of nicergoline in patients with multi-infarct dementia
44. A 24-month, double-blind, placebo-controlled multicenter pilot study of the efficacy and safety of nicergoline 60 mg per day in elderly hypertensive patients with leukoaraiosis
45. Choline increases acetylcholine release and protects against the stimulation-induced decrease in phosphatide levels within membranes of rat corpus striatum
46. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly
47. Lecithin for dementia and cognitive impairment
48. Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels
49. Pharmacologic rationale for memantine in chronic cerebral hypoperfusion, especially vascular dementia
50. MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis
51. Memantine in severe dementia: Results of the 9M-BEST study (Benefit and Efficacy in Severely Demented Patients During Treatment with Memantine)
52. Medical cost savings from pentoxifylline therapy in chronic occlusive arterial disease
53. Clinical review: Pentoxifylline
54. Platelet resistance to prostacyclin: Enhancement of the antiaggregatory effect of prostacyclin by pentoxifylline
55. Suppressive effect of pentoxifylline on natural killer cell activity
56. The role of haemorrheological factors in the aging brain: Long-term therapy with pentoxifylline ('Trental' 400) in elderly patients with initial mental deterioration
57. Pentoxifylline in cerebrovascular dementia
58. EPMID: European Pentoxifylline Multi-Infarct Dementia Study
59. Propento-fylline (HWA 285), a neuroprotective glial cell modulator: Pharmacologic profile
60. Propentofylline
61. Clinical trials of propentofylline in vascular dementia. European/Canadian Propentofylline Study Group
62. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: Effects of selective phosphodiesterase inhibitors
63. Denbufylline in dementia: A double-blind controlled study
64. Hemorheological changes and overproduction of cytokines from immune cells in mild to moderate dementia of the Alzheimer's type: Adverse effects on cerebrovascular system
65. Pharmacological actions of sulodexide
66. Vascular Dementia Italian Sulodexide Study (VADISS). Clinical and biological results
67. A promising approach to the treatment of multi-infarct dementia
68. Hemorheology and HELP in multi-infarct dementia
69. Effects of ameliorated haemorheology on clinical symptoms in cerebrovascular disease
70. Heparin-mediated extracorporeal LDL/fibrinogen precipitation - HELP - In coronary and cerebral ischemia
71. Controlled clinical trial of daily aspirin therapy in multi-infarct dementia
72. Randomized clinical trial of daily aspirin therapy in multi-infarct dementia: A pilot study
73. Abstention from cigarette smoking improves cerebral perfusion among elderly chronic smokers
74. Prospective long-term control of mild hypertension and blood flow
75. Improved cognition after control of risk factors for multi-infarct dementia
76. Aspirin for vascular dementia
77. Triflusal
78. Pharmacological profile of triflusal. Comparison with acetylsalicylic acid
79. Effects of triflusal and acetylsalicylic acid on microthrombi formation in experimental brain ischemia
80. Triflusal vs. aspirin on the inhibition of human platelet and vascular cyclooxygenase
81. Efficiency of triflusal in vascular dementias
82. Triflusal in the prevention of vascular dementia: A pilot study
83. Ginkgo biloba for cerebral insufficiency
84. Ginkgo biloba inpatients with dementia and cognitive impairment. Cochrane Review
85. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia
86. A 26-week analysis of a double-blind, placebo-controlled trial of the Ginkgo biloba extract EGb 761 in dementia
87. Subarachnoid haemorrhage associated with Ginkgo biloba
88. Prospects for pharmacological intervention in Alzheimer disease
89. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease
90. Use of donepezil for vascular dementia: Preliminary clinical experience
91. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors
92. Effect of the thyrotropin releasing hormone analogue posatirelin (RGH 2202) on microanatomical changes induced by lesions of the nucleus basalis magnocellularis in the rat
93. Posatirelin in the treatment of vascular dementia: A double-blind multicentre study vs. placebo
94. Pharmacokinetic profile and endocrine effects of posatirelin treatment in healthy elderly subjects
95. Neurotrophic effects of cerebrolysin in animal models of excitotoxicity
96. Cerebrolysin reduces microglial activation in vivo and in vitro: A potential mechanism of neuroprotection
97. Clinical experience with cerebrolysin
98. Effects of enzymatic blood defibrination in subcortical arteriosclerotic encephalopathy
99. Effects of antithrombin on Binswanger's disease with antiphospholipid antibody syndrome
100. Hyperbaric oxygenation in subcortical frontal syndrome due to small artery disorders with leukoaraiosis
101. Hyperbaric oxygenation: A promising treatment for Binswanger's disease
102. Status of risk factors for vascular dementia
103. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial
104. Vascular dementia: A time to 'seize the moment'
105. Status of treatment of vascular dementia
106. Treatment of vascular dementia